Johnson & Johnson (JNJ) will release its quarterly financial results on October 15th, 2024. Before a firm releases its profits, it is crucial to account for any changes to revenue predictions. These changes are a critical indicator for forecasting future stock-related investor behavior.
JNJ Earnings Projection
According to projections, the quarter's earnings per share (EPS) would be $2.19, a 17.7% drop from last year. The corporation is anticipated to generate $22.19 billion in earnings for the quarter, a 3.9% rise over the same quarter last year.
Earnings are expected to be $10 each share yearly, a minor increase of 0.81% over the prior year. On the other hand, the estimated yearly income is $88.53 billion, representing a 4.82% drop from the previous year.
JNJ Revenue Segment Projection
In light of this viewpoint, let's examine the average estimations of some Johnson & Johnson indicators often monitored and predicted by Wall Street experts.
Analysts predict that 'Sales-MedTech-Total' will reach $8.07 billion. The estimate shows a shift of +8.2% from year to year.
According to analysts, 'Sales—Innovative Medicine—WW' is expected to reach $14.12 billion. The estimate suggests an annual change of +1.7%.
According to analysts, 'Sales—Innovative Medicine—Neuroscience—WW' is expected to hit $1.80 billion. The estimate shows a shift of +3.5% from year to year.
